Health and Human Services Secretary Robert F. Kennedy, Jr. certainly has had a busy couple of weeks.

His department recently fired its newly appointed head of the Centers for Disease Control and Prevention (CDC). This house-cleaning led to several dramatic resignations, including the BDSM-promoting former monkeypox czar.

Now Kennedy's team has made one of its boldest attacks on woke and narrative science yet: It has cut $122 million in funding spread over nearly 200 DEI and LGBT projects that most Americans don't want and definitely don't need.

The grants, funding 195 different projects, were determined by the Trump administration to focus too narrowly on sexual or racial minority groups -- drawing outrage from some holdover officials from the Biden administration and contributing to at least one high-profile resignation this week.

The precise savings are difficult to calculate due to the fact that some awards were partially dispensed and often span multiple years. Most of the grants were scrapped in March in cooperation with the Department of Government Efficiency (DOGE), but others were canceled as recently as this month.

Among the biggest grants to be axed was $5.5 million from the National Cancer Institute to Vanderbilt University Medical Center for the "Vanderbilt FIRST" initiative that aims to "recruit at least 18 tenure-track faculty from minoritized [sic] racial and ethnic groups," according to data reviewed by The Post.

The prestigious Nashville, Tenn., university has an endowment of more than $10 billion -- ranked among America's top 20 -- but said the funds were needed to "identify and eliminate organizational barriers that impede full participation, advancement, and thriving of racially diverse faculty in academia."

Kennedy apparently worked with the Department of Government Efficiency (DOGE) to determine where to drain funding. Several of the programs targeted smacked of racism in academia.

One of the largest grants to be tossed by Kennedy was $5.5 million from the National Cancer Institute intended for the Vanderbilt University Medical Center.

According to the Post, the purpose of the grant was for the 'Vanderbilt FIRST' initiative seeking to 'recruit at least 18 tenure-track faculty from minoritized racial and ethnic groups.'

Another program that Kennedy tore apart were payments to Drexel University of more than $4.6 million from the National Cancer Institute for 'Catalyzing Systemic Change at Drexel University to Support Diverse Faculty in Health Disparities Research.'

The university reportedly planned to use the money for 'mentoring and supporting diverse early-stage faculty dedicated to health disparities research.'

But wait! There is even more common-sense decision-making goodness to celebrate.

The HHS revoked emergency use authorizations and restricted vaccine eligibility mostly to seniors (65+) and younger people with specific high-risk medical conditions.

Under the new rules, people over age 65 will remain eligible to get the vaccines, but younger adults and children will need to establish they have an underlying condition such as asthma or obesity that puts them at higher risk of serious illness.

That potentially eliminates access among broad swaths of the public -- in a sharp break from the federal government's shaming and firing of adults who refused to be vaccinated in 2021 and 2022.

Booster shots previously were easy to get and dispensed alongside the annual flu shot, which does not require the recipient to have elevated risk.

FDA Commissioner Dr. Marty Makary notes that this move makes vaccine mandates no longer legally possible for health subjects.

Two administration officials said Jim O'Neill, the second-in-command at the Department of Health and Human Services, would supplant Susan Monarez, a longtime government scientist. O'Neill, a former investment executive who also served at the federal health department under President George W. Bush, does not have a medical background. The officials, who confirmed the change, requested anonymity to discuss personnel decisions before a public announcement.

By way of background: O'Neill is a longstanding advocate for deregulating drug approval processes, arguing that pharmaceutical companies should only have to prove safety, not efficacy, in clinical trials. He has also publicly questioned established drug regulations, as well as supported longevity and anti-aging initiatives, both in venture capital and nonprofit spheres.

For one, in a 2014 speech, O'Neill advocated for the idea of "progressive approval." He said that "we should reform FDA so it is approving drugs after their sponsors have demonstrated safety and let people start using them. ... Let's prove efficacy after they've been legalized."

Needless to say, this would be a huge change from the FDA's current mission and the biopharma industry's research methods, which rely on clinical trials that test whether a treatment actually works. O'Neill said such a change would streamline the regulatory process and reduce development costs.

Certainly, safety should be a critical factor for drug approval...as well as reliable and reproducible data on the efficacy of treatments.

But the evidence suggests that the Make America Healthy Again reforms are proceeding. Hopefully, the new system will work better than the old.

Given that we are no longer mindlessly funding DEI or gender inanity, I am hopeful.